GIP and GLP-1 activate certain receptors (binding sites) in the body that help regulate appetite
GLP-1 agonists and tirzepatide may cause unpleasant side effects including dizziness, headache, indigestion or upset stomach, nausea, vomiting, diarrhoea and feeling jittery
Like different antioxidant therapies, its effectiveness and safety are related to the administered dose
p53-pS15 is a major focal point in p53 activation to mediate p53-dependent transcription or growth arrest, Ser 15 phosphorylation triggers a sequence of additional sites phosphorylation in p53 (including Ser9, -20, -46 and Thr18) that contribute further to p53 activation 28
A new study found a potential link between taking GLP-1 medications and a decrease in the overall risk of developing obesity-related cancers in people without diabetes
There have been isolated case reports of renal impairment associated with high-dose chromium supplementation, though causality remains unclear